TAPIMMUNE AND MARKER THERAPEUTICS ANNOUNCE SUCCESSFUL CLOSING OF PREVIOUSLY ANNOUNCED MERGER AND FINANCING TapImmune Inc. changes name to Marker Therapeutics, Inc. To Commence Trading on NASDAQ Capital Market on Thursday

TAPIMMUNE AND MARKER THERAPEUTICS ANNOUNCE

SUCCESSFUL CLOSING OF

PREVIOUSLY ANNOUNCED MERGER AND FINANCING

Jacksonville, FL, October 17, 2018 -TapImmune Inc. (NASDAQ:

TPIV), today announced the closing of the previously announced merger with privately-held Marker Therapeutics, Inc. In connection

with the merger, TapImmune Inc. changed its name to Marker Therapeutics, Inc., and reincorporated from Nevada into Delaware. The

combined company will focus on the continued development and commercialization of T cell therapies. Beginning Thursday, October 18,

2018, the Company's stock will begin trading under the new ticker symbol "MRKR" on the Nasdaq Capital Market

and will have a new CUSIP number, 57055L 107.

"The closing of this merger marks a significant

milestone, since the combined company is well-positioned to become a leader in cancer immunotherapy, with potentially

transformative therapies," said Peter L. Hoang, CEO of Marker Therapeutics, Inc. "The combined company will

have exponentially superior capabilities and resources than either company had alone. With the transaction completed, we can

now push our clinical trials forward more efficiently with the full resources available to the combined company. We are

confident that our therapies can fundamentally improve therapeutic outcomes for patients with life-threatening diseases, and

drive life-changing results for patients suffering from a variety of terrible cancers."

Mr. Hoang continued, "In connection with the merger, we

welcome to our Board of Directors, John Wilson, Dr. Juan Vera and David Eansor, whose participation and future contributions will

enhance the future prospects of the combined company."

"This merger provides Marker's unique and highly

promising T cell therapies with an excellent combination of financial support, management capacity, and scientific expertise that

is expected to expedite a fundamental change in the lives of cancer patients," said John Wilson, CEO of the former Marker

Therapeutics, Inc., which changed its name to Marker Cell Therapy, Inc. in connection with the merger. "Our belief that this

merger provides the best path forward has been reinforced by events surrounding the transaction, including the significant capital

contribution made by highly discerning healthcare investors, led by New Enterprise Associates, the exclusive license with Baylor

College of Medicine that will allow us to leverage the vast capabilities of their Center for Cell and Gene Therapy going forward,

and by the willingness of Dr. James Allison (2018 Nobel Prize of Medicine recipient) and Dr. Padmanee Sharma (2018 Coley Award

in Tumor Immunology recipient) to join our internationally acclaimed founders (Drs. Malcolm Brenner, Cliona Rooney, and Helen Heslop)

on Marker's Scientific Advisory Board."

As a result of the merger, 13,914,255 shares of common stock

of the Company, and warrants to purchase 5,046,003 shares of common stock at an exercise price of $2.99 per share with a five-year

term, were issued to the prior stockholders of the former Marker Therapeutics, Inc., which will become a subsidiary of the combined

company and renamed Marker Cell Therapy, Inc.

Concurrent with the merger, the Company closed on the previously

announced private placement financing (the "Financing"). The aggregate offering size, before deducting the placement

agent fees and other offering expenses, was $70 million. The Company issued 17,500,000 shares of its common stock and issued warrants

to purchase 13,125,000 shares of common stock at an exercise price of $5.00 per share that will be exercisable for a period of

five years. The closing of the merger and the Financing were subject to the approval of TapImmune's stockholders as required

by NASDAQ Stock Market Rules. TapImmune's stockholders approved the issuance of the merger and Financing shares and warrants

at TapImmune's annual meeting which occurred on October 16, 2018.

The Financing proceeds will be used to advance the combined

company's novel T cell therapies into multiple Phase 2 clinical studies, build out infrastructure to support clinical and

manufacturing capabilities, and other corporate and general purposes.

Piper Jaffray & Co. served as sole lead placement agent

for the private placement, and Nomura Securities International, Inc. served as co-placement agent and exclusive financial advisor

in conjunction with the merger.

The securities issued in the merger and sold in the Financing

(together the "Securities") have not been registered under the Securities Act of 1933, as amended, or state securities

laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission or an

applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the Securities

and Exchange Commission covering the resale of the Securities, including the shares of common stock issuable upon exercise of the

warrants. If any of the Securities are unable to be included on the initial registration statement, the Company has agreed to file

subsequent registration statements until all the Securities have been registered.

As a result of the closing of the merger and the Financing,

the former Marker stockholders, after taking into account the issuance of shares in the Financing occurring concurrently with the

merger, now own, on a fully-diluted basis (assuming the exercise of all outstanding warrants and options), approximately 27.5%,

and TapImmune's current stockholders now own approximately 27.5%, of the Company's common stock.

Frederick Wasserman, who was appointed

Chairman of Marker's Board upon closing of the merger said, "The completion of the merger and financing provide a strong

foundation for Marker's future growth initiatives. We are now better positioned to develop new therapies for patients and

create value for our shareholders." Mr. Wasserman continued and noted, "We look forward to working with our three

new directors who are joining our Board. We also wish to recognize our former board members who left the Board in connection with

the merger (Glynn Wilson, Sherry Grisewood, Mark Reddish and Joshua Silverman) for their many contributions in helping the Company

reach this milestone event."

The Company will be relocating its corporate

headquarters to Houston, Texas to facilitate its collaboration with the research team at the Baylor College of Medicine. In conjunction

with its move, the Company plans to open a facility in Houston to conduct its operations and oversee its clinical trials.

President & Chief Executive Officer

Peter L. Hoang, accompanied by the senior management team and Board of Directors, will ring the Nasdaq Closing Bell to mark the

end of trading for today, October 17th.

The ceremony, which will take place between

3:45 p.m. and 4:15 p.m. Eastern Time, will stream live online at https://new.livestream.com/nasdaq/live.

About Marker Therapeutics, Inc. (formerly

We are a clinical-stage immuno-oncology company

specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies

and solid tumor indications. Marker's cell therapy technology is based on the selective expansion of non-engineered,

tumor-specific T cells that recognize tumor associated antigens (i.e. tumor targets) and kill tumor cells expressing those targets.

Once infused into patients, this population of T cells attacks multiple tumor targets and acts to activate the patient's

immune system to produce broad spectrum anti-tumor activity. Because Marker does not genetically engineer its T cells,

when compared to current engineered CAR-T and TCR-based approaches, its products (i) are significantly less expensive and

easier to manufacture, (ii) appear to be markedly less toxic, and (iii) are associated with meaningful clinical benefit. As a result,

Marker believes its portfolio of T cell therapies has a compelling therapeutic product profile, as compared to current gene-modified

CAR-T and TCR-based therapies.

Marker is also advancing a number of innovative

peptide- and gene-based immuno-therapeutics for the treatment of cancer and metastatic disease, including our Folate

Receptor Alpha program (TPIV200) for breast and ovarian cancers and our HER2/neu+ peptide antigen program (TPIV100/110) in Phase

II clinical trials. In parallel, we are developing a proprietary DNA expression technology named PolyStart to improve

the ability of the cellular immune system to recognize and destroy diseased cells.

Forward-Looking Statement Disclaimer

This release contains forward-looking information within

the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's

expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations

as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking

statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially

from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to any

inability to recognize the anticipated benefits of the merger and

the financing as well as the risks set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which

are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.

Tiberend Strategic Advisors, Inc.